Please login to the form below

Not currently logged in
Email:
Password:

Ipsen appoints Christel Bories as deputy CEO

Has senior experience in several industries

Ipsen Christel BoriesChristel Bories has joined French biopharma company Ipsen as its deputy CEO, effective today.

Bories (pictured right) has years of senior experience in French business, and currently holds several positions, including VP of think-tank La Fabrique de l'Industrie, chair of the strategy committee of electrical company Legrand and member of the board of directors of packaging company Smurfit Kappa and the bank Natixis.

Her main focus has been within the aluminium industry, including several years as director of strategy and management control at Pechiney.

Following the company's merger with Alcan, she then served as chair of Alcan Packaging and then chair of Alcan Engineered Products.

She also spent time as CEO of Constellium, which was created after Rio Tinto acquired Alcan and then sold off the Alcan Engineered Products business.

Marc de Garidel, chairman and CEO of Ipsen, said Bories' wide experience outside pharma would benefit the company.

“She will provide a new perspective on our activities and the group will benefit from her extensive experience both in France and internationally.

“In her various positions, Christel demonstrated strong know-how and proven effectiveness in operational management. Christel shares our values and her expertise will be valuable to accelerate Ipsen's development."

1st March 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics